SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: jesspro who wrote (4382)9/8/2016 10:10:24 PM
From: jaybe2 Recommendations

Recommended By
larryjoe
tktom

  Respond to of 4474
 
Definitely not a BCL-2 inhibitor in the works.

This MD Anderson study used venetoclax (ABT-199) and nilotinib, but likely any 2nd/3rd-gen TKI would show synergy. Other TKI combos trials are underway targeting leukemic stem cells (LSCs) including pona:
clinicaltrials.gov.

We also know venetoclax + pona is effective in PH+ ALL from this Univ. of Oregon study last year:
stm.sciencemag.org.